The CLL8 trial has demonstrated that SF3B1 and TP53 mutations are among the strongest prognostic factors in CLL patients receiving chemoimmunotherapy [25]. The gene discussed is SF3B1; the disease is B-cell chronic lymphocytic leukemia.